Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - Febru ...

If you purchased or acquired Fermi: (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2025 initial public offering (“IPO” or the “Offering”); and/or (b) securities between October 1, 2025 and December 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses and possible misleading statements made by the company [2][3]. Company Investigation - The investigation centers on whether Beta Bionics issued misleading statements or failed to disclose important information to investors [3]. - Following the announcement of fewer patient starts than analysts estimated for the fourth quarter, Beta Bionics' shares dropped approximately 37% on January 9, 2026 [3]. Legal Options for Investors - Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][4].

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. for allegedly making materially false and misleading statements regarding its mining operations, particularly at the Brook Mine, leading to significant investor losses during the specified class period [2][7]. Allegation Details - The lawsuit claims that Ramaco failed to disclose that no significant mining activity had commenced at the Brook Mine after its groundbreaking, and that the company overstated its development progress [7]. - A report by Wolfpack Research described the Brook Mine as a "hoax" and indicated that no active work had taken place, contradicting the company's positive statements about its operations [7]. Stock Performance - Following the publication of the Wolfpack Research report on October 23, 2025, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share, with unusually high trading volume [7].

Core Insights - Rezolute, Inc. is under investigation by Faruqi & Faruqi, LLP due to significant stock losses following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3]. Group 1: Company Performance - Rezolute's shares experienced a dramatic decline on December 11, 2025, dropping from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decrease [3][4]. - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing non-significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal and Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to contact them to discuss potential legal options [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 6, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Klarna Group plc (NYSE: KLAR) ("Klarna" or the "Company") on behalf of investors who purchased or otherwise acquired Klarna securities during the period of September 7, 2025 through December 22, 2025 (the "Class Period"), including shares issued pursuant and/or traceable to Klarna's September 2025 initial public offering ("IPO").Inve ...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) between June 5, 2023, and December 26, 2025, inclusive. You are hereby notified that the class action lawsuit Megan Dodge v. Mereo BioPharma Group plc, et al. (Case No. 1:26-cv-00988) has been commenced in the United States District ...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) investors of the March 9, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Ardent securities between July 18, 2024 through November 12, 2025 (“the Class Period”). Courts do not consider applications filed after the lead plaintiff deadline. The lead plaintiff oversees the litigation on b ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In BellRing (BRBR) To Contact Him Directly To Discuss Their Options If you purchased or acquired BellRing securities between November 19, 2024 and August 4, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...